Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Topscience Biotech specializes in R&D, production, sales of Sodium Hyaluronate, focusing on Cosmetics, Medical, Pharmaceutical Grade HA

    Virtual Booth

    Contact Supplier

    Alchem offers Phytochemical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    China

    Virtual Booth

    Contact Supplier

    Menu

    ATH434

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alterity Therapeutics Presents New Data from ATH434 Phase 2 Trial
    Alterity Therapeutics Presents New Data from ATH434 Phase 2 Trial

    10 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/10/3059151/0/en/Alterity-Therapeutics-Presents-Encouraging-New-Data-from-its-ATH434-Phase-2-Trial-in-Multiple-System-Atrophy-at-the-American-Academy-of-Neurology-Annual-Meeting.html

    GLOBENEWSWIRE
    10 Apr 2025
    Share Share
    Alterity Therapeutics to Present Positive ATH434 Phase 2 Results
    Alterity Therapeutics to Present Positive ATH434 Phase 2 Results

    03 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/03/3055030/0/en/Alterity-Therapeutics-to-Deliver-an-Oral-Presentation-of-the-Positive-ATH434-Phase-2-Trial-Results-at-the-American-Academy-of-Neurology-Annual-Meeting.html

    GLOBENEWSWIRE
    03 Apr 2025
    Share Share
    Alterity Reports Positive Interim Data For ATH434 In MSA Trial
    Alterity Reports Positive Interim Data For ATH434 In MSA Trial

    17 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/17/2914458/0/en/Alterity-Therapeutics-Reports-Positive-Interim-Data-from-ATH434-202-Phase-2-Clinical-Trial-in-Multiple-System-Atrophy.html

    GLOBENEWSWIRE
    17 Jul 2024
    Share Share
    Alterity Shows ATH434 Potential in Friedreich's Ataxia
    Alterity Shows ATH434 Potential in Friedreich's Ataxia

    29 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/29/2871126/0/en/Alterity-Therapeutics-Presents-New-Data-Demonstrating-Potential-of-ATH434-to-Treat-Rare-Neurodegenerative-Disease-Friedreich-s-Ataxia.html

    GLOBENEWSWIRE
    29 Apr 2024
    Share Share
    Alterity Therapeutics Presents New Data at World Orphan Drug Congress
    Alterity Therapeutics Presents New Data at World Orphan Drug Congress

    10 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/10/2860644/0/en/Alterity-Therapeutics-to-Present-New-Data-on-ATH434-at-the-World-Orphan-Drug-Congress-USA-2024.html

    GLOBENEWSWIRE
    10 Apr 2024
    Share Share